Lansforsakringar Fondforvaltning Ab (Publ) Vertex Pharmaceuticals Inc Transaction History
Lansforsakringar Fondforvaltning Ab (Publ)
- $17 Billion
- Q2 2025
A detailed history of Lansforsakringar Fondforvaltning Ab (Publ) transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Lansforsakringar Fondforvaltning Ab (Publ) holds 141,290 shares of VRTX stock, worth $57.9 Million. This represents 0.37% of its overall portfolio holdings.
Number of Shares
141,290
Previous 136,311
3.65%
Holding current value
$57.9 Million
Previous $66.1 Million
4.82%
% of portfolio
0.37%
Previous 0.42%
Shares
3 transactions
Others Institutions Holding VRTX
# of Institutions
1,786Shares Held
235MCall Options Held
1.96MPut Options Held
1.14M-
Capital World Investors Los Angeles, CA28.7MShares$11.8 Billion1.94% of portfolio
-
Vanguard Group Inc Valley Forge, PA24.2MShares$9.92 Billion0.15% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$8.73 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA16.1MShares$6.6 Billion1.5% of portfolio
-
State Street Corp Boston, MA11.8MShares$4.82 Billion0.2% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $105B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...